| Customization: | Available |
|---|---|
| CAS No.: | 1801959-12-5 |
| Formula: | C35h55n11o9 |
|
Still deciding? Get samples of US$ 15/vial
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
In the realm of biomedical research, peptides have garnered significant attention due to their versatility in various therapeutic applications.
One such peptide that has been the subject of growing interest is PE-22-28, a promising compound that has shown great potential in addressing numerous health challenges.
If you are a beginner to Peptide Therapy then you can view our Peptide Therapy introduction guide and also book a consultation with us to learn more about Peptide Therapy homepage.
In this article, we will explore the intricacies of PE-22-28, delving into its composition, mechanisms of action, and its implications in various fields of medicine.
Supported by recent research and studies, this article aims to shed light on the multifaceted potential of PE-22-28 as a therapeutic agent.
PE-22-28 is a relatively short peptide composed of 22 to 28 amino acids. These amino acids are the building blocks of proteins and play vital roles in various biological processes. PE-22-28 is synthesised in the laboratory using solid-phase peptide synthesis, a precise and controlled method to create peptides with high purity.
The peptide's exact sequence may vary depending on its intended purpose and design, such as some studies who designed their desired length of the peptide, making it a versatile tool for researchers and clinicians. Its inherent biocompatibility and low immunogenicity contribute to its appeal as a therapeutic agent. Moreover, PE-22-28 can be easily modified to enhance its stability and biological activity, allowing for tailored applications.
| Items | Specifications |
| Business Type | We are a manufacturer of GMP peptide and provide OEM service. The lid also can be customized |
| Filling amount | The filling amount is 2-5mg extra per bottle. |
| Purity | The purity is above 99% |
| Price | Competitive price |
| Delivery time | The delivery time is stable and short. If you pay before 12 a.m,the goods can be shipped on the same day. |
| Shipping risk | If the package was lost we will resend the goods to you,so you won't suffer a loss if you buy it. |
Zhaobo Bio acquired early mastery of development and manufacturing of peptides, the short chain amino acids linked by peptide bonds that have enabled new generations of small molecule drugs that closely mimic the body's natural pathways.
Now Zhaobo Bio possesses first-class capabilities to manufacture peptides at industrial scale and in full compliance with the strictest Good Manufacturing Practice (GMP) standards.
Upstream peptide synthesis
Zhaobo Bio production plants are endowed with state-of-the-art equipment for solvent supply, peptide synthesis, purification and isolation of active ingredients and intermediates. All equipment and containment is GMP qualified and cleaning validated. Overlapping capacities and sizes of different equipment trains facilitate a smooth scale-up for increases in demand within the product life cycle.
Downstream purification and isolation of peptides
Zhaobo Bio is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of ever-increasing amounts of bulk peptide pharmaceuticals.
It uses sophisticated methods for large scale purification campaigns such as preparative high performance liquid chromatography (HPLC), ion exchange (IEX), size-exclusion chromatography (SEC), and ultra-filtration (UF/TFF). The equipment in place permits highly efficient or even continuous manufacturing of extremely pure products up to multi-kg quantities per lot.
For preparative HPLC, dynamic axial compression (DAC) stainless steel columns of up to 60 cm diameter both in batch and continuous mode are packed with the appropriate high performance silica separation phase. For low-pressure chromatography columns up to 80 cm diameter are available. Solvent delivery is ensured from eluent tank farms and containers.
The control of microbiological contamination is a prerequisite for API manufacturing. Class D (ISO 8) and C (ISO 7) clean rooms are supplied via HEPA-filtered, temperature and humidity controlled air, down-flow booths are used for minimizing microbial contamination and protecting operators. Highly active pharmaceutical ingredients are handled in integrated safety workbenches or flexible isolators reaching OEB level 4 (1-10 µg/m3).
Predefined physicochemical properties of the API can only be achieved by a carefully controlled isolation process. Besides precipitation and crystallization, lyophilization of intermediates and final API is a standard unit operation. LaixingPharma have multiple lyophilizers in different sizes (up to 300 liters) located in clean rooms.
){kind=link}